Partnerships & Alliances
Filter News
Found 52,340 articles
-
Sarepta Therapeutics and its partner, Roche, presented promising functional data from several trials of its gene therapy for Duchenne muscular dystrophy.
-
Boehringer, Evotec and bioMérieux found Aurobac to combat antimicrobial resistance, Turnstone and Moffitt Expand TIL Collab, Skyhawk to gain potential $2B from Sanofi RNA splicing deal.
-
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
7/6/2022
BeiGene and InnoRNA will jointly research a number of mRNA-LNP programs, and BeiGene will hold exclusive global development and commercialization rights for the product candidates from the programs.
-
VUMC and Roivant Social Ventures Announce Collaboration to Develop Therapies for Underserved Populations
7/6/2022
Vanderbilt University Medical Center (VUMC) and Roivant Social Ventures (RSV) announced an intention to collaborate in developing therapies for traditionally underserved populations and diseases.
-
Inmagene and HUTCHMED Announce First Participants in Global Phase I Trial of IMG-007
7/6/2022
Inmagene Biopharmaceuticals (" Inmagene ") and HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) announce today that the first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody.
-
Evotec, Boehringer Ingelheim, and bioMérieux Launch Aurobac, a Joint Venture to Fight Antimicrobial Resistance
7/6/2022
Evotec SE, Boehringer Ingelheim, a leading research-driven biopharmaceutical company, and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Boehringer Ingelheim, Evotec and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
7/6/2022
Boehringer Ingelheim, a leading research-driven biopharmaceutical company, the life science company Evotec SE and bioMérieux, a world leader in in vitro diagnostics, announced that they have formed a joint venture to create the next generation of antimicrobials along with actionable diagnostics to fight Antimicrobial Resistance.
-
Bumrungrad International Hospital, Southeast Asia's Largest Hospital to Deploy Lunit's AI Cancer Screening System
7/5/2022
Lunit and FujiFilm Thailand to supply Lunit INSIGHT CXR and Lunit INSIGHT MMG to one of SEA's largest hospital using Microsoft Azure Aim to detect cancer in early stages and spearhead medical innovation through AI across the SEA region.
-
Enosi Therapeutics Partners with Danuo Science Group to Accelerate Multiple Therapeutic Programs
7/5/2022
Enosi Therapeutics, a Delaware Corporation, focused on providing industry-leading therapeutics for cancer and autoimmune diseases, has announced a partnership with Danuo Science Group, based in Hong Kong, to further develop two products currently in Enosi's pipeline for Greater China.
-
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
7/5/2022
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type.
-
Touchlight Signs Patent License Agreement With Pfizer for the Use of dbDNA for the Manufacture of mRNA-based Vaccines, Therapeutics and Gene Therapies
7/5/2022
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable the genetic medicine revolution, today announces a non-exclusive patent license agreement with Pfizer.
-
Walden Biosciences Announces Research Collaboration with University of Michigan
7/5/2022
Walden Biosciences, Inc. (Walden), a private, venture-backed biotechnology company focused on transforming the treatment of kidney disease, today announced that the Company has entered into a research collaboration with the University of Michigan at Ann Arbor (U-M).
-
Skyhawk Announces Collaboration Agreement with Sanofi for Oncology and Immunology Targets
7/5/2022
Companies to leverage Skyhawk's proprietary SkySTAR™ platform to discover and develop novel small molecules that modulate RNA splicing to address challenging oncology and immunology targets.
-
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
7/5/2022
Urovant Sciences and Pierre Fabre Médicament today announced they have entered into an exclusive license agreement for Pierre Fabre to register and commercialize vibegron for the treatment of Overactive Bladder (OAB).
-
BIOLASE ANNOUNCES SUPPORT FOR TEAMSMILE PROGRAM
7/5/2022
BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced a partnership today with TeamSmile.
-
Unravel Biosciences Partners with TMA Precision Health to Advance Drug Treatment for Rett Syndrome into the Clinic
7/5/2022
Unravel Biosciences, Inc. ("Unravel"), today announced a partnership with TMA Precision Health ("TMA"), a Startup Health platform for rare diseases, aimed at identifying rare Rett Syndrome patients for inclusion in Unravel's first-in-human reformulated drug trial.
-
Aurigene Discovery Technologies Limited Announces Drug Discovery, Development and Commercialization Partnership with EQRx
7/5/2022
The collaboration combines Aurigene’s small molecule drug discovery platform and EQRx's pioneering business model to accelerate the development of drug candidates in the areas of oncology and immune-inflammatory diseases and improve global access to innovative medicines.
-
CEPI and Codiak BioSciences partner to develop broadly protective Betacoronavirus vaccine
7/5/2022
CEPI, the Coalition for Epidemic Preparedness Innovations, and Codiak BioSciences announced the latest funding award under CEPI’s US $200m programme to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other Betacoronaviruses.